Early Phase 2 Trial Data Support Safety, Efficacy of BBT-401 for Ulcerative Colitis

Early Phase 2 Trial Data Support Safety, Efficacy of BBT-401 for Ulcerative Colitis
0
(0)

People with ulcerative colitis may benefit from the experimental oral therapy BBT-401, suggest early data from an ongoing Phase 2 clinical trial that also supports its good safety profile.

BBT-401 is a small molecule that inhibits the activity of a protein called Pellino-1, which is involved in inflammatory responses. By blocking Pellino-1, BBT-401 may limit inflammatory processes that drive ulcerative colitis.

Preclinical studies in rodent disease models have supported this potential. A Phase 1 clinical trial in healthy volunteers also showed that BBT-401 was safe and well-tolerated.

Discovered by researchers at Sungkyunkwan University and the Korea Research Institute of Chemical Technology, BBT-401 was licensed to Bridge Biotherapeutics in 2015.

BBT-401 is currently being investigated in a placebo-controlled and dose-escalation Phase 2 clinical trial (NCT03800420) in up to 40 adults with ulcerative colitis at sites across the U.S.

Patients are being randomized to treatment with BBT-401 (at one of three doses) for 12 weeks then four weeks of placebo, or to a placebo for eight weeks followed by eight weeks of treatment. All enrolled had a Total Mayo Score of five or higher and Mayo Endoscopic Score of one or higher (Mayo Score is a measure of disease activity for ulcerative colitis.)

Bridge disclosed top-line, eight-week data for 11 of the 12 people in a first group ready for evaluation. Nine were given BBT-401 as a lower dose oral capsule, and three were given a placebo.

Three of these nine patients (33%) were responders — defined as a more than 30% reduction in Total Mayo Score or 25% reduction in Partial Mayo Score. None of the trial participants given placebo were responders.

The treatment was confirmed to be well-tolerated, with no serious adverse events reported. The only side effect found possibly related to the therapy was mild flatulence. In keeping with previous findings in animal models and human volunteers, BBT-401’s activity was confirmed to be limited to the gut.

Bridge Biotherapeutics plans to give subsequent enrolled groups higher doses of BBT-401 to further test its safety and efficacy.

“With the data from the first dose group in the phase 2a study, our team is encouraged to advance the clinical trial to higher doses. We will continue working to deliver this novel compound to patients with active ulcerative colitis,” James Lee, CEO of Bridge Biotherapeutics, said in a press release.

“Along with the interim results, Daewoong Pharmaceutical will further accelerate research and development of BBT-401, closely working in a collaboration with Bridge Biotherapeutics,” added Sengho Jeon, CEO of Daewoong Pharmaceutical.

Bridge Biotherapeutics sublicensed rights to the therapy in certain Asian countries to Daewoong Pharmaceutical in 2018.

Marisa holds an MS in Cellular and Molecular Pathology from the University of Pittsburgh, where she studied novel genetic drivers of ovarian cancer. She specializes in cancer biology, immunology, and genetics. Marisa began working with BioNews in 2018, and has written about science and health for SelfHacked and the Genetics Society of America. She also writes/composes musicals and coaches the University of Pittsburgh fencing club.
Total Posts: 34
Patrícia holds her PhD in Medical Microbiology and Infectious Diseases from the Leiden University Medical Center in Leiden, The Netherlands. She has studied Applied Biology at Universidade do Minho and was a postdoctoral research fellow at Instituto de Medicina Molecular in Lisbon, Portugal. Her work has been focused on molecular genetic traits of infectious agents such as viruses and parasites.
×
Marisa holds an MS in Cellular and Molecular Pathology from the University of Pittsburgh, where she studied novel genetic drivers of ovarian cancer. She specializes in cancer biology, immunology, and genetics. Marisa began working with BioNews in 2018, and has written about science and health for SelfHacked and the Genetics Society of America. She also writes/composes musicals and coaches the University of Pittsburgh fencing club.
Latest Posts
  • phage therapy BX002
  • risankizumab, Crohn's remission
  • CHMP favorable opinion
  • sweat sensor

How useful was this post?

Click on a star to rate it!

Average rating 0 / 5. Vote count: 0

No votes so far! Be the first to rate this post.

As you found this post useful...

Follow us on social media!

We are sorry that this post was not useful for you!

Let us improve this post!

Tell us how we can improve this post?